Latest Breaking News On - Wanbang biopharm - Page 1 : comparemela.com

The Proportion of Revenue from Innovative Products Continues to Increase Highlights: Revenue for the year ended December 31, 2021 was RMB39,005 million,.

South sudanUnited statesHong kongHan li kang rituximabYi baoWanbang biopharmYao pharmaWu yifangFosun pharmaAxicabtagene ciloleucelGuilin pharmaXin avatrombopagHan li kangSinopharm co ltdShanghai fosun pharmaceutical group co ltdVaccines division